Senseonics Holdings Inc. (SENS) Stock Sees Surge with Groundbreaking Glucose Monitoring System

Tuesday, Jun 3, 2025 12:46 am ET1min read
SENS--

Senseonics (SENS) has a unique continuous glucose monitoring system, Eversense 365, approved for a full year of use, setting it apart from traditional systems. Analyst Sean Lee initiated coverage with a Buy rating and $1.10 price target. 2 analysts predict an average price target of $2.00, a 282.04% upside from the current price of $0.52. The company reported a 24% increase in net revenue for Q1 2025 and announced the integration of Eversense 365 with SQL's Twist Automated Insulin Delivery System.

Senseonics Holdings Inc. (SENS) Stock Sees Surge with Groundbreaking Glucose Monitoring System

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet